ADENOSCAN
LOE ApproachingNDAINTRAVENOUSSOLUTION
Approved
May 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
2/8 — Basic
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADENOSCAN is an intravenous small-molecule diagnostic agent approved in 1995 by Astellas. The drug is used as a cardiac stress test agent to assess myocardial perfusion in patients unable to exercise. It works by simulating the effects of exercise on the heart to evaluate blood flow to heart muscle.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), the brand team is likely focused on lifecycle management and defending market share rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR)
Started Mar 2012
48 enrolled
Coronary Artery Disease
ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Started Apr 2004
787 enrolled
Coronary Artery Disease
ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Started Oct 2003
1,231 enrolled
Coronary Artery Disease
Career Relevance
Working on ADENOSCAN offers exposure to mature product management and defensive commercial strategy in a stable diagnostic market. Roles emphasize reimbursement defense, customer retention, and competitive positioning rather than growth-focused innovation.
Worked on ADENOSCAN at Astellas? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.